Below are the doses studied: Weekly injection: 1 mg 3 mg 6 mg 9 mg 6/9 mg (dose escalation) 3/6/9 mg (dose escalation) Some participants followed a step-up dosing schedule, meaning their dose was gradually increased over time
Understanding why these changes occur, what to expect, and when symptoms require medical attention helps patients manage treatment effectively whilst maintaining therapeutic benefits
Highlights from study findings include: 751 individuals participated in the study The mean percent change in weight at week 72 was -20.2% for those taking tirzepatide and -13.7% for those taking semaglutide The most common side effects were gastrointestinal A 2025 real-world study of over 2,300 patients treated at an academic obesity clinic also showed meaningful weight loss, especially among those who stayed on therapy for at least a year
Results are gradual and depend on consistency
Consumers are eating less, gravitating toward nutrient-dense foods, and showing different purchase patterns than in the past
10.1038/NRI.2017.142 123 TsibrisJ